1. Home
  2. OSUR vs CRDF Comparison

OSUR vs CRDF Comparison

Compare OSUR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OraSure Technologies Inc.

OSUR

OraSure Technologies Inc.

SELL

Current Price

$3.55

Market Cap

256.6M

Sector

Health Care

ML Signal

SELL

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$0.86

Market Cap

67.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSUR
CRDF
Founded
2000
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
256.6M
67.1M
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
OSUR
CRDF
Price
$3.55
$0.86
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$5.50
★ $6.28
AVG Volume (30 Days)
★ 638.2K
346.5K
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.37
EPS
★ N/A
N/A
Revenue
★ $167,064,000.00
$365,993.00
Revenue This Year
$4.64
N/A
Revenue Next Year
$9.04
$5.62
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 49.61
52 Week Low
$2.08
$0.71
52 Week High
$4.58
$3.31

Technical Indicators

Market Signals
Indicator
OSUR
CRDF
Relative Strength Index (RSI) 45.77 49.74
Support Level $2.78 $0.77
Resistance Level $4.11 $1.13
Average True Range (ATR) 0.24 0.07
MACD -0.02 0.01
Stochastic Oscillator 28.88 70.96

Price Performance

Historical Comparison
OSUR
CRDF

About OSUR OraSure Technologies Inc.

OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: